View in EDS HTML Full Text PDF Full Text

Plonmarlimab, a novel anti‐GM‐CSF blocking antibody, ameliorates disease progression in the pre‐clinical model of macrophage activation syndrome.

Saved in:
Bibliographic Details
Title: Plonmarlimab, a novel anti‐GM‐CSF blocking antibody, ameliorates disease progression in the pre‐clinical model of macrophage activation syndrome.
Authors: Ding, Jian1 (AUTHOR), Xu, Ke1 (AUTHOR), Niu, Yanling1 (AUTHOR), Qin, Yihui1 (AUTHOR), Shen, Hong2 (AUTHOR), Wang, Yajuan1 (AUTHOR), Guo, Wenyu1 (AUTHOR), Liu, Xuejun1 (AUTHOR), Wang, Zhengyi1 (AUTHOR), Zhu, Andrew X.1 (AUTHOR) andrew.zhu@tjbio.com
Source: Immunology. Nov2024, Vol. 173 Issue 3, p552-561. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:00192805
DOI:10.1111/imm.13842